BEDMINSTER, N.J., Jan. 2 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:
NPSP) announced today the appointment of Alan G. Harris, M.D., Ph.D., as
senior vice president and chief medical officer.
Francois Nader, M.D., executive vice president and chief operating
officer, stated: "Alan brings impressive credentials and industry experience
to NPS and will play a critical role in leading the company's research and
development programs for GATTEX, PREOS and NPSP156. We welcome his insights
and contributions as we focus on obtaining regulatory approvals and expanding
the potential indications for these innovative product candidates."
Before joining NPS, Dr. Harris was chief medical officer of Manhattan
Pharmaceuticals, therapeutic head of worldwide medical endocrine care at
Pfizer, Inc., and vice president of global health research and outcomes at
Schering-Plough Corp. where he held a variety of senior medical affairs
positions. While at Sandoz (now Novartis), Dr. Harris developed, as project
leader, the first long-acting somatostatin analogue, octreotide (Sandostatin
(R)), for the treatment of gastrointestinal tumors and endocrine diseases.
Dr. Harris currently holds several academic appointments, including
adjunct professor in the department of pharmacology at NYU Medical Center in
New York, and was previously associate professor of medicine at UCLA Medical
School and director of the division of clinical pharmacology in the department
of medicine at Cedars-Sinai Medical Center. He has authored over 100
peer-reviewed scientific articles. Dr. Harris is a fellow of the American
College of Physicians and a fellow of the Royal College of Physicians (UK).
Dr. Harris received his doctor of medicine degree from the University of
Strasbourg, France and his Ph.D. in endocrinology from Erasmus University,
Rotterdam, The Netherlands. He undertook post-graduate training in
hepatogastroenterology and nutrition from Nice University Medical School,
NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant proteins
as drugs, primarily for the treatment of metabolic, bone and mineral, and
central nervous system disorders. The company has drug candidates in various
stages of clinical development. Additional information is available on the
company's website, http://www.npsp.com.
Note: Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. All information in this press release is as of January 2, 2008 and
we undertake no duty to update this information. A more complete description
of these risks can be found in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year-ended
December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended
September 30, 2007.
For further information:
For further information: Brandi Simpson of NPS Pharmaceuticals, Inc.,
+1-908-450-5616 Web Site: http://www.npsp.com